Cargando…

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab

BACKGROUND: Low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice. HYPOTHESIS: We assessed LDL‐C lowering during 1 year of evolocumab ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Nihar R., Wade, Rolin L., Xiang, Pin, Pinto, Lionel, Nunna, Sasikiran, Wang, Xin, Exter, Jason, Mues, Katherine E., Habib, Mohdhar, Chen, Chi‐Chang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119857/ https://www.ncbi.nlm.nih.gov/pubmed/33760276 http://dx.doi.org/10.1002/clc.23600

Ejemplares similares

Patient characteristics and acute cardiovascular event rates among patients with very high‐risk and non‐very high‐risk atherosclerotic cardiovascular disease
por: Fonarow, Gregg C., et al.
Publicado: (2021)

Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States
por: Baum, Seth J., et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified
por: Baum, Seth J, et al.
Publicado: (2019)

Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis
por: Cheng, Cheng, et al.
Publicado: (2016)

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
por: Shah, Parth, et al.
Publicado: (2017)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)
por: Shaik, Aleesha, et al.
Publicado: (2022)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes
por: Lotta, Luca A., et al.
Publicado: (2018)

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
por: Daviglus, Martha L., et al.
Publicado: (2020)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates
por: Pinto, Lionel, et al.
Publicado: (2022)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels
por: Sajja, Aparna, et al.
Publicado: (2021)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

Low-density lipoprotein cholesterol lowering treatment: the current approach
por: Crismaru, Irina, et al.
Publicado: (2020)

Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults
por: Chiang, Jui-Kun, et al.
Publicado: (2011)

Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels
por: Pandya, Ankur, et al.
Publicado: (2018)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
por: Colhoun, Helen M., et al.
Publicado: (2020)

Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults
por: Kim, Joungyoun, et al.
Publicado: (2021)

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　― Data From a Real-World Observational Study of Evolocumab in Japan ―
por: Yokote, Koutaro, et al.
Publicado: (2019)

Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity?
por: Li, Chaoyang, et al.
Publicado: (2008)

Association Between Low-Density Lipoprotein Cholesterol Levels and Risk for Sepsis Among Patients Admitted to the Hospital With Infection
por: Feng, QiPing, et al.
Publicado: (2019)

High‐density lipoprotein cholesterol levels are associated with major adverse cardiovascular events in male but not female patients with hypertension
por: Wang, Xiaopu, et al.
Publicado: (2021)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography
por: WANG, Yao, et al.
Publicado: (2020)

Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
por: Elsadek Seaoud, Elshaimaa Aly M., et al.
Publicado: (2022)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome
por: Biswas, Hope H., et al.
Publicado: (2015)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity
por: Zhang, Chao, et al.
Publicado: (2015)

The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol
por: Durakoğlugil, Murtaza Emre, et al.
Publicado: (2015)

Visit-to-visit variability in low-density lipoprotein cholesterol is associated with adverse events in non-obstructive coronary artery disease
por: Gu, Jun, et al.
Publicado: (2019)

Association of Coronary Plaque With Low-Density Lipoprotein Cholesterol Levels and Rates of Cardiovascular Disease Events Among Symptomatic Adults
por: Mortensen, Martin Bødtker, et al.
Publicado: (2022)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eu7gp85kcmcd3b9vvtifebrolo